Oncological Management of Medulloblastoma and New Viral Therapeutic Targets
Medulloblastoma (MB) is one of the most prevalent
brain tumours among paediatrics. Although its management has
evolved over time still there is need to find new therapeutic targets
for MB that can result in less normal tissue toxicity while improving
survival and reducing recurrence. This literature review is aimed at
finding new potential therapeutic targets for MB focusing on viruses
that can be used as potential targets for MB. The review also gives an
over-view of management of paediatric Medulloblastoma focusing on
Radiotherapy management.
[1] K. Chao, C. Perez, and L. Brady, eds. Radiation Oncology Management
Decisions. Philadelphia: Lippincott Williams & Wilkins, 2002.
[2] A. Brandes, and M. Paris, “Review of the prognostic factors in
medulloblastoma of children and adults,” Critical Reviews in Oncology /
Hematology, 50, 121-128, 2004
[3] A. Paulino, “Current multimodality management of medulloblastoma,”
Current problems in Cancer, 26, 317-356. 2002.
[4] P. Plowman, and A. Pearson, “Tumours of the central nervous system,”
in Paediatric Oncology. Clinical Practice and Controversies, 2nd ed. C.
Pinkerton, and P. Plowman P, eds. London: Chapman & Hall, 1997.
[5] R. Packer, “Childhood medlloblastoma: progress and future challenges,”
Brain and Development, 21, 75-81, 1999.
[6] Bomford, and I. Kunkler, Walter and Miller’ Textbook of Radiotherapy:
radiation physics, therapy and oncology. 3rd ed. Edinburgh: Churchill
Livingstone, 2003.
[7] Louis, H. Ohgaki, O. Wiestler, et al., eds. WHO Classification of
Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC
Press, 2007.
[8] M. Taylor, P. Northcott, A. Korshunov, M. Remke, Y. Chao, S. Clifford
et al., “Molecular subgroups of medulloblastoma: the current
consensus,” Aceta Neuropathologica, 123, 465-472, 2012.
[9] M. Kool, A. Korshunov, M. Remke, D. Jones, M. Schlanstein, P.
Northcott, et al., “Molecular subgroups of medulloblastoma: An
international meta-analysis of transcriptome, genetic aberrations, and
clinical data of wnt, shh, group 3, and group 4 medulloblastomas,” Acta
Neuropathologica, 123, 473-84, 2012.
[10] R. Potter, T. Czech, I. Slavc, Wimberger-Prayer, and H. Budka,
“Tumours of the central nervous system,” in Cancer in children, P.
Voute, C. Kalifa C, and A. Barrett, eds. Oxford: Oxford University
Press, 1998.
[11] M. Fouladi, A. Gajjar, J. Boyett, A. Walter, S. Thompson, T. Merchant,
et al., "Comparison of CSF cytology and spinal magnetic resonance
imaging in the detection of leptomeningeal disease in pediatric
meduloblastoma or primitive neuroectodermal tumor," Journal Clinical
Oncology, 17, 3234-3237, 1999.
[12] R. Taylor, “United Kingdom Children’s Cancer Study Group
(UKCCSG) Radiotherapy and Brain Tumour Groups:
Medulloblastoma/PNET and Craniospinal Radiotherapy (CSRT): Report
of a Workshop held in Leeds,” Clinical Oncology, 13, 58-64, 1999.
[13] J. Phi, J. Lee, K. Wang, B. Cho, I. Kim, and C. Park, “Cerebrospinal
fluid M staging for medulloblastoma: Reappraisal of Chang's M staging
based on the CSF flow,” Neuro-Oncology, 13, 334-344, 2011.
[14] Michiels, J. Heikens, M. Jansen, F. Oldenburger, & T. Voute, “Are
clinical parameters valuable prognostic factors in childhood primitive
neuroectodermal tumours? A multivariate analysis of 105 cases,”
Radiotherapy & Oncology, 54, 229-238, 2000.
[15] Jenkin, M. Al Shabanah, E. Al Shail, A. Gray, M. Hssounah, Y.
Khafaga, et al., “Prognostic factors for medulloblastoma,” International
Journal of Radiation Oncology, Biology, Physics, 47, 573-584, 2000.
[16] S. Rieken, A.. Moher, D. Hebermehl, T. Welzel, K. Lindel, O. Witt, et
al., “Outcome and Prognostic factors of radiation therapy for
medulloblastoma,” International Journal of Radiation Oncology,
Biology, Physics, 81, e7-e13, 2011.
[17] O. Araujo, K. de Trindade, N. Trompieri, J. Fontenele, and F. Felix,
“Analysis of survival and prognostic factors of pediatric patients with
brain tumor,” Journal of Pediatric (Rio J), 87, 425–32, 2011
[18] M. Massimino, M. Antonelli, L. Gandola, R. Miceli, B. Pollo, V.
Biassoni, et al., “Histological variants of medulloblastoma are the most
powerful clinical prognostic indicators,” Pediatric Blood Cancer, 60,
210-6, 2013.
[19] Z. Shinwari, H. Al-Hindi, E. Al-Shail, Y. Khafaga, A. Al-Kofide, N. Al-
Kum, et al., “Response of Medulloblastoma Cells to Vincristine and
Lomustine: Role of TRKC, CTNNB1, and STK15,” Anticancer
Research, 31, 1721-1734, 2011.
[20] A. Ellison, O. Onilude, J. Lindsey, M. Lusher, C. Weston, and R.
Taylor, “β-Catenin status predicts a favorable outcome in childhood
medulloblastoma: the United Kingdom Children’s Cancer Study Group
Brain Tumour Committee,” Journal of Clinical Oncology, 23, 7951-
7957, 2005.
[21] K. Neben, A. Korshunov, A. Benner, G. Wrobel, M. Hahn, and F.
Kokocinski, “Microarray based screening for molecular markers in
medulloblastoma revealed STK15 as independent predictor for
survival,” Cancer Research, 64, 3103-3111, 2004.
[22] Z. Zhang, J. Xu, Y. Ren, Y. Yao, K. Li, H. Ng, et al., “Medulloblastoma
in China: Clinicopathologic Analyses of SHH, WNT, and non-
SHH/WNTMolecular subgroups Reveal Different Therapeutic
Responses to Adjuvant Chemotherapy,” PLoS ONE, 9, e99490.
Available online: http://www.brainlife.org/fulltext/2014/
Zhang_ZY140616.pdf. (Accessed 06/01/2015).
[23] Albright, L. Wisoff, P. Zeltzer, J. Boyett, L. Rorke, and P. Stanley,
“Effects of medulloblastoma resections on outcome in children: a report
from the children’s cancer group,” Neurosurgery, 38, 265-271, 1996.
[24] Y. Khafaga, A. Kandil, A. Jamshed, M. Hassounah, E. DeVol, and A.
Gray A., “Treatment results for 149 medulloblastoma patients from one
institution,” International Journal of Radiation Oncology, Biology,
Physics, 35, 501-506, 1996.
[25] R. Taylor, C. Bailey, K. Robinson, C. Weston, D. Ellison, J. Ironside, et
al., “Impact of radiotherapy parameters on outcome in the International
Society of Paediatric Oncology/United Kingdom Children’s Cancer
Study Group PNET-3 study of preradiotherapy chemotherapy for M0-
M1 medulloblastoma,” International Journal of Radiation Oncology,
Biology, Physics, 58, 1184-1193, 2004
[26] L. Sun, S. Yeh, C. Wang, E. Huang, H. Chen, and H. Hsu,
“Postoperative radiation therapy for medulloblastoma – high recurrence
rate in the subfrontal region,” Journal of Neuro-Oncology, 58, 77-85,
2002.
[27] R. Taylor, C. Bailey, K. Robinson, C. Weston, D. Ellison, J. Ironside, et
al., “Results of a Randomized Study of Preradiation Chemotherapy
Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The
International Society of Paediatric Oncology / United Kingdom
Children’s Cancer Study Group PNET-3 Study,” Journal of Clinical
Oncology, 21, 1581-1591, 2003.
[28] J. Douglas, J. Barker, R. Ellenbogen, and J. Geyer, “Concurrent
chemotherapy and reduced dose cranial spinal irradiation followed by
conformal posterior fossa tumour bed boost for average-risk
medulloblastoma: efficacy and patterns of failure,” International
Journal of Radiation Oncology Biology, Physics, 58, 1161-1164, 2004.
[29] R. Packer, J. Golwein, H. Nicholson, L. Vezina, J. Allen and M. Ris et
al., “Treatment of children with medulloblastoma with reduced
craniospinal radiation therapy and adjuvant chemotherapy: a children’s
cancer group study,” Journal of Clinical Oncology, 17, 2127–2136,
1999. [30] P. Thomas, M. Deutsch, J. Kepner, J. Boyett, J. Krischer, P. Aronin, et
al., “Low-stage medulloblastoma: final analysis of trial comparing
standard-dose with reduced-dose neuraxis Irradiation,” Journal of
Clinical Oncology, 18, 3004-11, 2000.
[31] R. Jakacki, H. Feldman, C. Jamison, J. Boaz, T. Luerssen, and R.
Timmerman, “A pilot study of preirradiation chemotherapy and 1800
cGy craniospinal irradiation in young children with medulloblastoma,”
International Journal of Radiation Oncology, Bioliogy, Physics, 60,
531-536, 2004.
[32] A. Freeman, R. Taylor, R. Kortmann, and C. Carrie, “Radiotherapy for
medulloblastoma in children: a perspective on current international
clinical research effort,” Medical and Pediatric Oncology, 39, 99–108,
2002.
[33] A. Bouffet, J. Gentet, F. Doz, P. Tron, H. Roche, and D. Plantaz et al.,
“Metastatic Medulloblastoma: the experience of the French Cooperative
M7 Group,” European Journal of Cancer, 30, 1478-1483. 1994.
[34] K. Mah, C. Danjoux, S. Manship, N. Makhani, M. Cardoso, and K.
Sixel, “Computed tomographic simulation of craniospinal fields in
pediatric patients: improved treatment accuracy and patient comfort,”
International Journal of Radiation Oncology, Biology, Physics, 41, 997-
1003, 1998.
[35] A. Chang, P. Wong, K. Forser, M. Petru, A. Kowalski, and M. Maor M.,
“Verification Techniques and Dose Distribution for Computed
Tomographic Planned Supine Craniospinal Radiation Therapy,” Medical
Dosimetry, 28, 127-131, 2003.
[36] R. Miralbell, A. Bleher, P. Huguenin, G. Ries, R. Kann, R. Mirimanoff,
et al., “Paediatric medulloblastoma: Radiation treatment technique and
pattern of failure,” International Journal of Radiation oncology,
Biology, Physics, 37, 523-529, 1997.
[37] J. Dobbs, A. Barrett, and D. Ash, Practical Radiotherapy Planning. 3rd
ed. London: Edward Arnold, 1999.
[38] A. Narayana, S. Jeswani, and A. Paulino, “The Cranial-spinal Junction
in Medulloblastoma: Does it Matter?,”’ International Journal of
Radiation Oncology, Biology, Physics, 44, 81-84, 1999.
[39] A. Scharf, A. Paulino, and K. Golberg, “Determination of the inferior
border of the thecal sac using magnetic resonance imaging: implications
on radiation therapy treatment planning,” International Journal of
Radiation Oncology, Biology, Physics, 41, 621-624, 1998.
[40] A. Paulino, A. Narayana, M. Mohideen, and S. Jeswani S., “Posterior
fossa boost in medulloblastoma: an analysis of dose to surrounding
structures using 3-dimensional (conformal) radiotherapy,” International
Journal of Radiation Oncology, Biology, Physics, 46, 281-286, 2000.
[41] A. Paulino, B. Wen, N. Mayr, R. Tannous, T. Loew, F. Goldman, et al.,
“Protracted Radiotherapy Treatment Duration in Medulloblastoma,”
American Journal of Clinical Oncology, 26, 55-59, 2003.
[42] W. Hartsell, A. Guijar, R. Heidemann, J. Langston, R. Sanford, A.
Walter, et al., “Patterns of failure in children with medulloblastoma:
Effects of preirradiation chemotherapy,” International Journal of
Radiation Oncology, Biology, Physics, 39, 15-24, 1997.
[43] J. Kortann, J. Kuhl, B. Timmerman, U. Mittler, C. Urban, V. Budach, et
al., “Postoperative chemotherapy before radiotherapy as compared to
immediate radiotherapy followed by maintenance chemotherapy in the
treatment of medulloblastoma in childhood: results of the German
prospective randomized trial HIT 91,” International Journal of
Radiation Oncology, Biology, Physics, 46, 269-279, 2000.
[44] A. Paulino, A. Mazloom, B. Teh, M. South, M. Okcu, J. Su et al., “
Local Control after Craniospinal Irradiation, Intensity Modulated
Radiotherapy Boost, and Chemotherapy in Childhood
Medulloblastoma,” Cancer, 117, 635-641, 2011.
[45] A. Paulino, M. Lobo, B. Teh, M. Okcu, M. South, E. Butler et al.,
“Ototoxicity after inten- sity-modulated radiation therapy and cisplatinbased
chemo-therapy in children with medulloblastoma,” International
Journal of Radiation Oncology, Biology, Physics, 78, 1445-50, 2010.
[46] E. Huang, B. Teh, D. Strother, Q. Davis, J. Chiu, H. Lu, et al.,
“Intensity-modulated radiation therapy for pediatric medulloblastoma:
early report on the reduction of ototoxicity,” International Journal of
Radiation Oncology, Biology, Physics, 52, 599-605, 2002.
[47] P. Myers, P. Mavroidis, N. Papanikolaou, and S. Stathakis, “Comparing
Conformal arc radiotherapy and helical tomotherapy in craniospinal
irradiation planning,” Journal of Applied Clinical Medical Physics, 15,
12-28, 2014.
[48] Graham, and T. Cloughesy, “Brain tumour treatment: Chemotherapy and
other new developments,” Seminars in Oncology Nursing, 20, 260-272,
2004.
[49] M. Hopkins, J. Pownall, and L. Scott L. “Acute and sub acute side
effects of radiotherapy,” in Paediatric Oncology: Acute Nursing Care,
F. Gibson, and M. Evans, eds. London: Whurr Publishers Ltd, 2000.
[50] S. Harden, N. Twyman, D. Lomas, D. Williams, N. Burnet, and M.
Williams, “A method for reducing ovarian doses in whole neuro-axis
irradiation for medulloblastoma,” Radiotherapy and Oncology, 69, 183-
188, 2003.
[51] S. Muirhead, E. Hsu, L. Grimard, and D. Keene, “Endocrine
cmplications of Pediatric brain tumours: case series and literature
review,” Paediatric Neurology, 27, 165-170, 2002.
[52] L. Scott, J. Pownall, and M. Hopkins, “Late effects of radiotherapy,” in
Paediatric Oncology: Acute Nursing Care, F. Gibson, and M. Evans,
eds. London: Whurr Publishers Ltd, 2000.
[53] J. Grill, V. Renaux, C. Bulteau, D. Viguier, C. Levy-Piebois, C. Sainte-
Rose, et al., “Long-term intellectual outcome in children with posterior
fossa tumours according to radiation doses and volumes,” International
Journal of Radiation Oncology, Biology, Physics, 45, 37-145, 1999.
[54] Reeves, S. Palmer, W. Reddick, T. Merchant, G. Buchanan, and A.
Gajjar, “Attention and memory functioning among paediatric patients
with medulloblastoma,” Journal of Pediatric Psychology, 31, 272-80,
2006.
[55] K. Nishiyama, S. Funakoshi, S. Izumuto, T. Ikeda, and Y. Oku, “Longterm
effects of radiation for medulloblastoma on intellectual and
physical development. A case report of monozygotic twins,” Cancer, 73,
2450-2455, 1994.
[56] S. Oberfield, D. Chin, N. Uli, R. David, C. Sklar, “Endocrine late effects
of childhood Cancers,” The Journal of Pediatrics, 131, S37-S41, 1997.
[57] R. Mulhern, T. Merchant, A. Gajjar, W. Reddick, and L. Kun L., “Late
neurocognitive sequelae in survivors of brain tumours in childhood,”
The Lancet Oncology, 5, 399-408, 2004.
[58] R. Packer, A. Gajjar, G. Vezina, L. Rorke-Adams, P. Burger, P.
Robertson, et al., “Phase III study of craniospinal radiation therapy
followed by adjuvant chemotherapy for newly diagnosed average-risk
medulloblastoma,” Journal of clinical Oncology,24, 4202–4208, 2006.
[59] J. Heikens, E. Michiels, H. Behrendt, E. Endert, P. Bakker, and E. Fliers,
“Long-term neuro-endocrine sequelae after treatment for childhood
medulloblastoma,” European Journal of Cancer, 34, 1592–1597, 1998.
[60] T. Merchant, E. Kiehna, C. Li, H. Shukla, S. Sengupta, X. Xiong, et al.,
“Modeling radiation dosimetry to predict cognitive outcomes in
pediatric patients with CNS embryonal tumors including
medulloblastoma,” International Journal of Radiation Oncology,
Biology, Physics, 65, 210–221, 2006.
[61] N. Baryawno, A. Rahbar, N. Wolmer-Solberg, C. Taher, J. Odeberg, A.
Darabi et al., “Detection of Human Cytomegalovirus in
medulloblastoma reveals a potential therapeutic target,” Journal of
Clinical Investigation, 121, 4043-4055, 2011.
[62] J. Odeberg, N. Wolmer, S. Falci, M. Westgren, A. Seiger, C. Soderberg-
Naucler, “Human cytomegalovirus inhibits neuronal differentiation and
induces apoptosis in human neural precursor cells,” Journal of Virology,
80, 8929–8939, 2006. Available at: http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC1563895/pdf/0676-06.pdf. (Accessed 07/01/2015)
[63] J. Odeberg, N. Wolmer, S. Falci, M. Westgren, E. Sundtrom, A. Seiger,
et al., “Late human cytomegalovirus (HCMV) proteins inhibit
differentiation of human neural precursor cells into astrocytes,” Journal
of Neuroscience Research, 85, 583–593, 2007
[64] P. Scotting, D. Walker, and G. Perilongo, “Childhood solid tumours: a
developmental disorder,” Nature Reviews Cancer, 5, 481–488, 2005.
[65] Maussang, E. Langemeijer, C. Fitzsimon, M. Stigter-van, R. Dijkman,
M. Borg et al., “The human cytomegalovirusencoded chemokine
receptor US28 promotes angiogenesis and tumor formation via
cyclooxygenase-2,” Cancer Research, 69, 2861–2869, 2009.
[66] Wang, and R. Dubois, “Eicosanoids and cancer,” Nature Review
Cancer, 10, 181–193, 2010.
[67] J. Mrena, J. Wiksten, A. Thiel, A. Kokkola, L. Pohjola, J. Lundin et al.,
“Cyclooxygenase-2 is an independent prognostic factor in gastric cancer
and its expression is regulated by the messenger RNA stability factor
HuR,”. Clinical Cancer Research. 11, 7362–7368m 2005. Available at:
http://clincancerres.aacrjournals.org/content/11/20/7362.full.pdf+html.
(Accessed 05/01/2015).
[68] L. Soumaoro, H. Uetake, T. Higuchi, Y. Takagi, M. Enomoto, and K.
Sugihara, “Cyclooxygenase-2 expression: a significant prognostic
indicator for patients with colorectal cancer,” Clinical Cancer Research,
10, 8465–8471, 2004. [69] M. Michaelis and J. Cinatl, “The Story of Human Cytomegalovirus and
Cancer; Increasing evidence and Open Questions,” Neoplasia, 11, 1-9,
2009.
[70] J. Cinatl, J. Cinatl, J. Vogel, H. Rabenau, B. Kornhuber, and H. Doerr
“Modulatory effects of human cytomegalovirus infection on malignant
properties of cancer cells,” Intervirology, 39, 259-269, 1996.
[71] J. Cinatl, J. Vogel, J. Cinatl, B. Weber, H. Rabenau, M. Novak, et al.,
“Long-term productive human cytomegalovirus infection of a human
neuroblastoma cell line,” International Journal of Cancer, 65, 90–96,
1996.
[72] J. Cinatl, J. Cinatl, J. Vogel, R. Kotchetkov, P. Driever, H. Kabickova, et
al., “Persistent human cyto-megalovirus infection induces drug
resistance and alteration of programmed cell death in human
neuroblastoma cells,” Cancer Research, 58 , 367–372, 1998.
[73] J. Cinatl, J. Vogel, R. Kotchetkov, and H. Wilhelm “Oncomodulatory
signals by regulatory proteins encoded by human cytomegalovirus: a
novel role for viral infection in tumor progression,” FEMS Microbiology
Reviews, 28 ,59–77, 2004.
[74] Söderberg-Nauclér, “HCMV microinfections in inflammatory diseases
and cancer,” Journal of Clinical Virology, 41, 218 – 223, 2008.
[75] Wang, and R. Dubois, “Prostaglandins and cancer,” Gut, 55, 115-22,
2006.
[76] Zhou, D. Li, M. Resnick, J. Wands, and W. Cao, “NADPH Oxidase
NOX5-S and Nuclear factor kB1 Mediate Acid-induced microsomal
Prostaglandin E Synthase-1 Expression in Barrett’s Esophageal
Adenocarcinoma Cells,” Molecular Pharmacology, 83, 978-990, 2013.
[77] Tai, C. Ensor, M. Tong M, H. Zhou, F. Yan, “Prostaglandin catabolizing
enzymes,” Prostaglandins & Other Lipid Mediators, 68–69, 483–493,
2002.
[78] Tai, M. Tong, and Y. Ding Y, “15-hydroxyprostaglandin dehydrogenase
(15-PGDH) and lung cancer,” Prostaglandins & Other Lipid
Mediators, 83, 203-8, 2007.
[79] S. Myung, and I. Kim, “Role of prostaglandins in colon cancer,” The
Korean Journal of Gastroenterology, 51, 274-9, 2008.
[80] S. Myung, R. Rerko, M. Yan, P. Platzer, K. Guda, A. Dotson, et al., “15-
Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon
tumorigenesis,” Proceedings of the National Academy of Sciences of
United States of America, 103, 12098-102.13, 2006.
[81] Pharm, M. Chen, A. Li, “Loss of 15-Hydroxyprostaglandin
Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumours,”
National Institute of Health, 39, 332-339, 2010.
[82] Galanis, “Therapeutic potential of oncolytic measles virus: promises and
challenges,” Clinical Pharmacology and Therapeutics, 88, 620–625,
2010.
[83] A. Studebaker, C. Kreofsky, C. Pierson, S. Russell, E. Galanis, and C.
Raffel C, “Treatment of medulloblastoma with a modified measles
virus,” Neuro Oncology, 12, 1034–1042, 2010.
[84] A. Studebaker, B. Hutzen, C. Pierson, S. Russell, E. Galanis, C. Raffel,
“Oncolytic measles virus prolongs survival in a murine model of
cerebral spinal fluiddisseminated medulloblastoma,” Neuro Oncology,
14, 459–470, 2012.
[85] Hutzen, H. Bid, P. Houghton, C. Pierson, K. Powell, A. Bratasz, et al.,
“Treatment of medulloblastoma with oncolytic measles viruses
expressioning the angiogenesis inhibitors endostatin and angiostatin,”
BioMedical Central Cancer, 14, 2014.
[1] K. Chao, C. Perez, and L. Brady, eds. Radiation Oncology Management
Decisions. Philadelphia: Lippincott Williams & Wilkins, 2002.
[2] A. Brandes, and M. Paris, “Review of the prognostic factors in
medulloblastoma of children and adults,” Critical Reviews in Oncology /
Hematology, 50, 121-128, 2004
[3] A. Paulino, “Current multimodality management of medulloblastoma,”
Current problems in Cancer, 26, 317-356. 2002.
[4] P. Plowman, and A. Pearson, “Tumours of the central nervous system,”
in Paediatric Oncology. Clinical Practice and Controversies, 2nd ed. C.
Pinkerton, and P. Plowman P, eds. London: Chapman & Hall, 1997.
[5] R. Packer, “Childhood medlloblastoma: progress and future challenges,”
Brain and Development, 21, 75-81, 1999.
[6] Bomford, and I. Kunkler, Walter and Miller’ Textbook of Radiotherapy:
radiation physics, therapy and oncology. 3rd ed. Edinburgh: Churchill
Livingstone, 2003.
[7] Louis, H. Ohgaki, O. Wiestler, et al., eds. WHO Classification of
Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC
Press, 2007.
[8] M. Taylor, P. Northcott, A. Korshunov, M. Remke, Y. Chao, S. Clifford
et al., “Molecular subgroups of medulloblastoma: the current
consensus,” Aceta Neuropathologica, 123, 465-472, 2012.
[9] M. Kool, A. Korshunov, M. Remke, D. Jones, M. Schlanstein, P.
Northcott, et al., “Molecular subgroups of medulloblastoma: An
international meta-analysis of transcriptome, genetic aberrations, and
clinical data of wnt, shh, group 3, and group 4 medulloblastomas,” Acta
Neuropathologica, 123, 473-84, 2012.
[10] R. Potter, T. Czech, I. Slavc, Wimberger-Prayer, and H. Budka,
“Tumours of the central nervous system,” in Cancer in children, P.
Voute, C. Kalifa C, and A. Barrett, eds. Oxford: Oxford University
Press, 1998.
[11] M. Fouladi, A. Gajjar, J. Boyett, A. Walter, S. Thompson, T. Merchant,
et al., "Comparison of CSF cytology and spinal magnetic resonance
imaging in the detection of leptomeningeal disease in pediatric
meduloblastoma or primitive neuroectodermal tumor," Journal Clinical
Oncology, 17, 3234-3237, 1999.
[12] R. Taylor, “United Kingdom Children’s Cancer Study Group
(UKCCSG) Radiotherapy and Brain Tumour Groups:
Medulloblastoma/PNET and Craniospinal Radiotherapy (CSRT): Report
of a Workshop held in Leeds,” Clinical Oncology, 13, 58-64, 1999.
[13] J. Phi, J. Lee, K. Wang, B. Cho, I. Kim, and C. Park, “Cerebrospinal
fluid M staging for medulloblastoma: Reappraisal of Chang's M staging
based on the CSF flow,” Neuro-Oncology, 13, 334-344, 2011.
[14] Michiels, J. Heikens, M. Jansen, F. Oldenburger, & T. Voute, “Are
clinical parameters valuable prognostic factors in childhood primitive
neuroectodermal tumours? A multivariate analysis of 105 cases,”
Radiotherapy & Oncology, 54, 229-238, 2000.
[15] Jenkin, M. Al Shabanah, E. Al Shail, A. Gray, M. Hssounah, Y.
Khafaga, et al., “Prognostic factors for medulloblastoma,” International
Journal of Radiation Oncology, Biology, Physics, 47, 573-584, 2000.
[16] S. Rieken, A.. Moher, D. Hebermehl, T. Welzel, K. Lindel, O. Witt, et
al., “Outcome and Prognostic factors of radiation therapy for
medulloblastoma,” International Journal of Radiation Oncology,
Biology, Physics, 81, e7-e13, 2011.
[17] O. Araujo, K. de Trindade, N. Trompieri, J. Fontenele, and F. Felix,
“Analysis of survival and prognostic factors of pediatric patients with
brain tumor,” Journal of Pediatric (Rio J), 87, 425–32, 2011
[18] M. Massimino, M. Antonelli, L. Gandola, R. Miceli, B. Pollo, V.
Biassoni, et al., “Histological variants of medulloblastoma are the most
powerful clinical prognostic indicators,” Pediatric Blood Cancer, 60,
210-6, 2013.
[19] Z. Shinwari, H. Al-Hindi, E. Al-Shail, Y. Khafaga, A. Al-Kofide, N. Al-
Kum, et al., “Response of Medulloblastoma Cells to Vincristine and
Lomustine: Role of TRKC, CTNNB1, and STK15,” Anticancer
Research, 31, 1721-1734, 2011.
[20] A. Ellison, O. Onilude, J. Lindsey, M. Lusher, C. Weston, and R.
Taylor, “β-Catenin status predicts a favorable outcome in childhood
medulloblastoma: the United Kingdom Children’s Cancer Study Group
Brain Tumour Committee,” Journal of Clinical Oncology, 23, 7951-
7957, 2005.
[21] K. Neben, A. Korshunov, A. Benner, G. Wrobel, M. Hahn, and F.
Kokocinski, “Microarray based screening for molecular markers in
medulloblastoma revealed STK15 as independent predictor for
survival,” Cancer Research, 64, 3103-3111, 2004.
[22] Z. Zhang, J. Xu, Y. Ren, Y. Yao, K. Li, H. Ng, et al., “Medulloblastoma
in China: Clinicopathologic Analyses of SHH, WNT, and non-
SHH/WNTMolecular subgroups Reveal Different Therapeutic
Responses to Adjuvant Chemotherapy,” PLoS ONE, 9, e99490.
Available online: http://www.brainlife.org/fulltext/2014/
Zhang_ZY140616.pdf. (Accessed 06/01/2015).
[23] Albright, L. Wisoff, P. Zeltzer, J. Boyett, L. Rorke, and P. Stanley,
“Effects of medulloblastoma resections on outcome in children: a report
from the children’s cancer group,” Neurosurgery, 38, 265-271, 1996.
[24] Y. Khafaga, A. Kandil, A. Jamshed, M. Hassounah, E. DeVol, and A.
Gray A., “Treatment results for 149 medulloblastoma patients from one
institution,” International Journal of Radiation Oncology, Biology,
Physics, 35, 501-506, 1996.
[25] R. Taylor, C. Bailey, K. Robinson, C. Weston, D. Ellison, J. Ironside, et
al., “Impact of radiotherapy parameters on outcome in the International
Society of Paediatric Oncology/United Kingdom Children’s Cancer
Study Group PNET-3 study of preradiotherapy chemotherapy for M0-
M1 medulloblastoma,” International Journal of Radiation Oncology,
Biology, Physics, 58, 1184-1193, 2004
[26] L. Sun, S. Yeh, C. Wang, E. Huang, H. Chen, and H. Hsu,
“Postoperative radiation therapy for medulloblastoma – high recurrence
rate in the subfrontal region,” Journal of Neuro-Oncology, 58, 77-85,
2002.
[27] R. Taylor, C. Bailey, K. Robinson, C. Weston, D. Ellison, J. Ironside, et
al., “Results of a Randomized Study of Preradiation Chemotherapy
Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The
International Society of Paediatric Oncology / United Kingdom
Children’s Cancer Study Group PNET-3 Study,” Journal of Clinical
Oncology, 21, 1581-1591, 2003.
[28] J. Douglas, J. Barker, R. Ellenbogen, and J. Geyer, “Concurrent
chemotherapy and reduced dose cranial spinal irradiation followed by
conformal posterior fossa tumour bed boost for average-risk
medulloblastoma: efficacy and patterns of failure,” International
Journal of Radiation Oncology Biology, Physics, 58, 1161-1164, 2004.
[29] R. Packer, J. Golwein, H. Nicholson, L. Vezina, J. Allen and M. Ris et
al., “Treatment of children with medulloblastoma with reduced
craniospinal radiation therapy and adjuvant chemotherapy: a children’s
cancer group study,” Journal of Clinical Oncology, 17, 2127–2136,
1999. [30] P. Thomas, M. Deutsch, J. Kepner, J. Boyett, J. Krischer, P. Aronin, et
al., “Low-stage medulloblastoma: final analysis of trial comparing
standard-dose with reduced-dose neuraxis Irradiation,” Journal of
Clinical Oncology, 18, 3004-11, 2000.
[31] R. Jakacki, H. Feldman, C. Jamison, J. Boaz, T. Luerssen, and R.
Timmerman, “A pilot study of preirradiation chemotherapy and 1800
cGy craniospinal irradiation in young children with medulloblastoma,”
International Journal of Radiation Oncology, Bioliogy, Physics, 60,
531-536, 2004.
[32] A. Freeman, R. Taylor, R. Kortmann, and C. Carrie, “Radiotherapy for
medulloblastoma in children: a perspective on current international
clinical research effort,” Medical and Pediatric Oncology, 39, 99–108,
2002.
[33] A. Bouffet, J. Gentet, F. Doz, P. Tron, H. Roche, and D. Plantaz et al.,
“Metastatic Medulloblastoma: the experience of the French Cooperative
M7 Group,” European Journal of Cancer, 30, 1478-1483. 1994.
[34] K. Mah, C. Danjoux, S. Manship, N. Makhani, M. Cardoso, and K.
Sixel, “Computed tomographic simulation of craniospinal fields in
pediatric patients: improved treatment accuracy and patient comfort,”
International Journal of Radiation Oncology, Biology, Physics, 41, 997-
1003, 1998.
[35] A. Chang, P. Wong, K. Forser, M. Petru, A. Kowalski, and M. Maor M.,
“Verification Techniques and Dose Distribution for Computed
Tomographic Planned Supine Craniospinal Radiation Therapy,” Medical
Dosimetry, 28, 127-131, 2003.
[36] R. Miralbell, A. Bleher, P. Huguenin, G. Ries, R. Kann, R. Mirimanoff,
et al., “Paediatric medulloblastoma: Radiation treatment technique and
pattern of failure,” International Journal of Radiation oncology,
Biology, Physics, 37, 523-529, 1997.
[37] J. Dobbs, A. Barrett, and D. Ash, Practical Radiotherapy Planning. 3rd
ed. London: Edward Arnold, 1999.
[38] A. Narayana, S. Jeswani, and A. Paulino, “The Cranial-spinal Junction
in Medulloblastoma: Does it Matter?,”’ International Journal of
Radiation Oncology, Biology, Physics, 44, 81-84, 1999.
[39] A. Scharf, A. Paulino, and K. Golberg, “Determination of the inferior
border of the thecal sac using magnetic resonance imaging: implications
on radiation therapy treatment planning,” International Journal of
Radiation Oncology, Biology, Physics, 41, 621-624, 1998.
[40] A. Paulino, A. Narayana, M. Mohideen, and S. Jeswani S., “Posterior
fossa boost in medulloblastoma: an analysis of dose to surrounding
structures using 3-dimensional (conformal) radiotherapy,” International
Journal of Radiation Oncology, Biology, Physics, 46, 281-286, 2000.
[41] A. Paulino, B. Wen, N. Mayr, R. Tannous, T. Loew, F. Goldman, et al.,
“Protracted Radiotherapy Treatment Duration in Medulloblastoma,”
American Journal of Clinical Oncology, 26, 55-59, 2003.
[42] W. Hartsell, A. Guijar, R. Heidemann, J. Langston, R. Sanford, A.
Walter, et al., “Patterns of failure in children with medulloblastoma:
Effects of preirradiation chemotherapy,” International Journal of
Radiation Oncology, Biology, Physics, 39, 15-24, 1997.
[43] J. Kortann, J. Kuhl, B. Timmerman, U. Mittler, C. Urban, V. Budach, et
al., “Postoperative chemotherapy before radiotherapy as compared to
immediate radiotherapy followed by maintenance chemotherapy in the
treatment of medulloblastoma in childhood: results of the German
prospective randomized trial HIT 91,” International Journal of
Radiation Oncology, Biology, Physics, 46, 269-279, 2000.
[44] A. Paulino, A. Mazloom, B. Teh, M. South, M. Okcu, J. Su et al., “
Local Control after Craniospinal Irradiation, Intensity Modulated
Radiotherapy Boost, and Chemotherapy in Childhood
Medulloblastoma,” Cancer, 117, 635-641, 2011.
[45] A. Paulino, M. Lobo, B. Teh, M. Okcu, M. South, E. Butler et al.,
“Ototoxicity after inten- sity-modulated radiation therapy and cisplatinbased
chemo-therapy in children with medulloblastoma,” International
Journal of Radiation Oncology, Biology, Physics, 78, 1445-50, 2010.
[46] E. Huang, B. Teh, D. Strother, Q. Davis, J. Chiu, H. Lu, et al.,
“Intensity-modulated radiation therapy for pediatric medulloblastoma:
early report on the reduction of ototoxicity,” International Journal of
Radiation Oncology, Biology, Physics, 52, 599-605, 2002.
[47] P. Myers, P. Mavroidis, N. Papanikolaou, and S. Stathakis, “Comparing
Conformal arc radiotherapy and helical tomotherapy in craniospinal
irradiation planning,” Journal of Applied Clinical Medical Physics, 15,
12-28, 2014.
[48] Graham, and T. Cloughesy, “Brain tumour treatment: Chemotherapy and
other new developments,” Seminars in Oncology Nursing, 20, 260-272,
2004.
[49] M. Hopkins, J. Pownall, and L. Scott L. “Acute and sub acute side
effects of radiotherapy,” in Paediatric Oncology: Acute Nursing Care,
F. Gibson, and M. Evans, eds. London: Whurr Publishers Ltd, 2000.
[50] S. Harden, N. Twyman, D. Lomas, D. Williams, N. Burnet, and M.
Williams, “A method for reducing ovarian doses in whole neuro-axis
irradiation for medulloblastoma,” Radiotherapy and Oncology, 69, 183-
188, 2003.
[51] S. Muirhead, E. Hsu, L. Grimard, and D. Keene, “Endocrine
cmplications of Pediatric brain tumours: case series and literature
review,” Paediatric Neurology, 27, 165-170, 2002.
[52] L. Scott, J. Pownall, and M. Hopkins, “Late effects of radiotherapy,” in
Paediatric Oncology: Acute Nursing Care, F. Gibson, and M. Evans,
eds. London: Whurr Publishers Ltd, 2000.
[53] J. Grill, V. Renaux, C. Bulteau, D. Viguier, C. Levy-Piebois, C. Sainte-
Rose, et al., “Long-term intellectual outcome in children with posterior
fossa tumours according to radiation doses and volumes,” International
Journal of Radiation Oncology, Biology, Physics, 45, 37-145, 1999.
[54] Reeves, S. Palmer, W. Reddick, T. Merchant, G. Buchanan, and A.
Gajjar, “Attention and memory functioning among paediatric patients
with medulloblastoma,” Journal of Pediatric Psychology, 31, 272-80,
2006.
[55] K. Nishiyama, S. Funakoshi, S. Izumuto, T. Ikeda, and Y. Oku, “Longterm
effects of radiation for medulloblastoma on intellectual and
physical development. A case report of monozygotic twins,” Cancer, 73,
2450-2455, 1994.
[56] S. Oberfield, D. Chin, N. Uli, R. David, C. Sklar, “Endocrine late effects
of childhood Cancers,” The Journal of Pediatrics, 131, S37-S41, 1997.
[57] R. Mulhern, T. Merchant, A. Gajjar, W. Reddick, and L. Kun L., “Late
neurocognitive sequelae in survivors of brain tumours in childhood,”
The Lancet Oncology, 5, 399-408, 2004.
[58] R. Packer, A. Gajjar, G. Vezina, L. Rorke-Adams, P. Burger, P.
Robertson, et al., “Phase III study of craniospinal radiation therapy
followed by adjuvant chemotherapy for newly diagnosed average-risk
medulloblastoma,” Journal of clinical Oncology,24, 4202–4208, 2006.
[59] J. Heikens, E. Michiels, H. Behrendt, E. Endert, P. Bakker, and E. Fliers,
“Long-term neuro-endocrine sequelae after treatment for childhood
medulloblastoma,” European Journal of Cancer, 34, 1592–1597, 1998.
[60] T. Merchant, E. Kiehna, C. Li, H. Shukla, S. Sengupta, X. Xiong, et al.,
“Modeling radiation dosimetry to predict cognitive outcomes in
pediatric patients with CNS embryonal tumors including
medulloblastoma,” International Journal of Radiation Oncology,
Biology, Physics, 65, 210–221, 2006.
[61] N. Baryawno, A. Rahbar, N. Wolmer-Solberg, C. Taher, J. Odeberg, A.
Darabi et al., “Detection of Human Cytomegalovirus in
medulloblastoma reveals a potential therapeutic target,” Journal of
Clinical Investigation, 121, 4043-4055, 2011.
[62] J. Odeberg, N. Wolmer, S. Falci, M. Westgren, A. Seiger, C. Soderberg-
Naucler, “Human cytomegalovirus inhibits neuronal differentiation and
induces apoptosis in human neural precursor cells,” Journal of Virology,
80, 8929–8939, 2006. Available at: http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC1563895/pdf/0676-06.pdf. (Accessed 07/01/2015)
[63] J. Odeberg, N. Wolmer, S. Falci, M. Westgren, E. Sundtrom, A. Seiger,
et al., “Late human cytomegalovirus (HCMV) proteins inhibit
differentiation of human neural precursor cells into astrocytes,” Journal
of Neuroscience Research, 85, 583–593, 2007
[64] P. Scotting, D. Walker, and G. Perilongo, “Childhood solid tumours: a
developmental disorder,” Nature Reviews Cancer, 5, 481–488, 2005.
[65] Maussang, E. Langemeijer, C. Fitzsimon, M. Stigter-van, R. Dijkman,
M. Borg et al., “The human cytomegalovirusencoded chemokine
receptor US28 promotes angiogenesis and tumor formation via
cyclooxygenase-2,” Cancer Research, 69, 2861–2869, 2009.
[66] Wang, and R. Dubois, “Eicosanoids and cancer,” Nature Review
Cancer, 10, 181–193, 2010.
[67] J. Mrena, J. Wiksten, A. Thiel, A. Kokkola, L. Pohjola, J. Lundin et al.,
“Cyclooxygenase-2 is an independent prognostic factor in gastric cancer
and its expression is regulated by the messenger RNA stability factor
HuR,”. Clinical Cancer Research. 11, 7362–7368m 2005. Available at:
http://clincancerres.aacrjournals.org/content/11/20/7362.full.pdf+html.
(Accessed 05/01/2015).
[68] L. Soumaoro, H. Uetake, T. Higuchi, Y. Takagi, M. Enomoto, and K.
Sugihara, “Cyclooxygenase-2 expression: a significant prognostic
indicator for patients with colorectal cancer,” Clinical Cancer Research,
10, 8465–8471, 2004. [69] M. Michaelis and J. Cinatl, “The Story of Human Cytomegalovirus and
Cancer; Increasing evidence and Open Questions,” Neoplasia, 11, 1-9,
2009.
[70] J. Cinatl, J. Cinatl, J. Vogel, H. Rabenau, B. Kornhuber, and H. Doerr
“Modulatory effects of human cytomegalovirus infection on malignant
properties of cancer cells,” Intervirology, 39, 259-269, 1996.
[71] J. Cinatl, J. Vogel, J. Cinatl, B. Weber, H. Rabenau, M. Novak, et al.,
“Long-term productive human cytomegalovirus infection of a human
neuroblastoma cell line,” International Journal of Cancer, 65, 90–96,
1996.
[72] J. Cinatl, J. Cinatl, J. Vogel, R. Kotchetkov, P. Driever, H. Kabickova, et
al., “Persistent human cyto-megalovirus infection induces drug
resistance and alteration of programmed cell death in human
neuroblastoma cells,” Cancer Research, 58 , 367–372, 1998.
[73] J. Cinatl, J. Vogel, R. Kotchetkov, and H. Wilhelm “Oncomodulatory
signals by regulatory proteins encoded by human cytomegalovirus: a
novel role for viral infection in tumor progression,” FEMS Microbiology
Reviews, 28 ,59–77, 2004.
[74] Söderberg-Nauclér, “HCMV microinfections in inflammatory diseases
and cancer,” Journal of Clinical Virology, 41, 218 – 223, 2008.
[75] Wang, and R. Dubois, “Prostaglandins and cancer,” Gut, 55, 115-22,
2006.
[76] Zhou, D. Li, M. Resnick, J. Wands, and W. Cao, “NADPH Oxidase
NOX5-S and Nuclear factor kB1 Mediate Acid-induced microsomal
Prostaglandin E Synthase-1 Expression in Barrett’s Esophageal
Adenocarcinoma Cells,” Molecular Pharmacology, 83, 978-990, 2013.
[77] Tai, C. Ensor, M. Tong M, H. Zhou, F. Yan, “Prostaglandin catabolizing
enzymes,” Prostaglandins & Other Lipid Mediators, 68–69, 483–493,
2002.
[78] Tai, M. Tong, and Y. Ding Y, “15-hydroxyprostaglandin dehydrogenase
(15-PGDH) and lung cancer,” Prostaglandins & Other Lipid
Mediators, 83, 203-8, 2007.
[79] S. Myung, and I. Kim, “Role of prostaglandins in colon cancer,” The
Korean Journal of Gastroenterology, 51, 274-9, 2008.
[80] S. Myung, R. Rerko, M. Yan, P. Platzer, K. Guda, A. Dotson, et al., “15-
Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon
tumorigenesis,” Proceedings of the National Academy of Sciences of
United States of America, 103, 12098-102.13, 2006.
[81] Pharm, M. Chen, A. Li, “Loss of 15-Hydroxyprostaglandin
Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumours,”
National Institute of Health, 39, 332-339, 2010.
[82] Galanis, “Therapeutic potential of oncolytic measles virus: promises and
challenges,” Clinical Pharmacology and Therapeutics, 88, 620–625,
2010.
[83] A. Studebaker, C. Kreofsky, C. Pierson, S. Russell, E. Galanis, and C.
Raffel C, “Treatment of medulloblastoma with a modified measles
virus,” Neuro Oncology, 12, 1034–1042, 2010.
[84] A. Studebaker, B. Hutzen, C. Pierson, S. Russell, E. Galanis, C. Raffel,
“Oncolytic measles virus prolongs survival in a murine model of
cerebral spinal fluiddisseminated medulloblastoma,” Neuro Oncology,
14, 459–470, 2012.
[85] Hutzen, H. Bid, P. Houghton, C. Pierson, K. Powell, A. Bratasz, et al.,
“Treatment of medulloblastoma with oncolytic measles viruses
expressioning the angiogenesis inhibitors endostatin and angiostatin,”
BioMedical Central Cancer, 14, 2014.
@article{"International Journal of Medical, Medicine and Health Sciences:68781", author = "A. Taqaddas", title = "Oncological Management of Medulloblastoma and New Viral Therapeutic Targets", abstract = "Medulloblastoma (MB) is one of the most prevalent
brain tumours among paediatrics. Although its management has
evolved over time still there is need to find new therapeutic targets
for MB that can result in less normal tissue toxicity while improving
survival and reducing recurrence. This literature review is aimed at
finding new potential therapeutic targets for MB focusing on viruses
that can be used as potential targets for MB. The review also gives an
over-view of management of paediatric Medulloblastoma focusing on
Radiotherapy management.
", keywords = "Cytomegalovirus, Measles Virus, Medulloblastoma, Radiotherapy.", volume = "9", number = "1", pages = "27-8", }
